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An Attempt to Reverse Diabetes by Delayed Islet Cell Transplantation 
in Humans 
C. Rasteilini, R. Shapiro, R. Corry, J.J. Fung, T.E. Starzl, and A.S. Rao 
ALTHOUGH autotransplantation of islets has been 
shown to successfully reverse pancreatectomy-in-
duced diabetes. such an outcome is rarelv witnessed after 
islet cell aliotransplantationKlK~ To prom~te acceptance of 
islets in diabetic patients suffering from end-stage renal 
disease (ESRD). perioperative infusion of donor bone 
marrow (BM) to augment chimerism has already been 
attempted.I .. ~ A less than desirable outcome of the latter 
approach has prompted the exploration of alternative strat-
egies which would allow for successful islet cell transplan-
tation (Tx). It has been previously shown that. unlike 
concomitant Tx. islets implanted subsequent to BM infu-
sion in rodents results in indefinite reversal of streptozoto-
cin-induced diabetes.4 However. despite its uniqueness, the 
principal limitation for clinical application of this procedure 
was the unpredictable islet cell recovery encountered using 
contemporary culture and cryopreservation techniques. 
Recognizing this predicament, we embarked on developing 
a novel technique that allowed for prolonged islet cell 
culture with an acceptable loss of their viability and func-
tion." This accomplishment motivated the initiation of a 
clinical trial for delayed islet cell infusion into diabetic 
kidney transplant recipients. who have exhibited demon-
strable immune modulation and are maintained on rela-
tively lower doses of immunosuppression (IS); reported 
herein is the clinical outcome in these patients. 
MATERIALS AND METHODS 
Patients 
Since June 1 <)<)5. four patients with insulin-depel1lknt tvpe I 
Jiahetie mellitus diagnosed with ESRD received cadaveric renal Tx 
(CRTx) wilh delayed (31 ttl .+) Jays post-CRTx) islet cell infusion. 
In two palients. chimerism was augmented with infusion of (, >: \Il" 
unmodified BM cells/kg body weight that were ohtained from the 
vertebral bodies of the cadaveric donor. Of these two recipients. 
one received BM as a single infusion at the time of organ Tx. 
whereas in the other. 1.2 X 10" cells/kg were infused over a period 
of 5 consecutive days heginning on the day of renal Tx. IS was with 
Tacrolimus, CellCept. and steroids. 
Islet Cell Isolation, Culture, and Infusion 
Islets were isolated from the pancreata ohtained from the kidney 
donors by a modification of the automated method described 
elsewhere." and subsequently purified by velocity sedimentation on 
a discontinuous Eurocollins-ficoll density gradient using a cell 
separator (COBE 2991. CO BE Laboratories Inc. Lakewood. 
Colo). Islet number. purity, and viability were determined by 
dithizone staining and in vitro dynamic peri fusion assay. A known 
concentration (60 to so IEq/mL) of isolated islets was cultured in 
pyruvate-enriched (5· to 7-mmol/L) medium supplemented with 5 
mmol/L D-glucose. 5% to 10% fetal calf serum and 25 mmol/L 
HEPES (GIBCO. Grand Island. NY). The cells were maintained at 
37°C in 5% CO2 in air until infused.5 The day of the isolation, 5 
days before. and on the day of the infusion. extensive microbiolog-
ical testing was performed to ensure the sterility of the preparation. 
Additionally. on the day of the infusion. islet number and viability 
were again determined by dithizone staining and in vitro dynamic 
perifusion assay. At the time of Tx. a known concentration (0.3 to 
1.3 x 10" IEq) of cultured iskts was infused using the percutaneous 
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Table 1. Graft Function in BM-Augmented and Nonaugmented Kidney + Delayed Islet Cell Transplant Recipients: 
Pallent 
Age 
{yr)/Gender 
32/M 
391M 
AbbreViations BM. bone marrow: Tx. transplant. 
Kidney-Delayed Islet-BM" 
Follow,up (rna) 
Kldnev Islet 
14 
5 
13 
.. 
'Averaqe ,nsul,n requirement (IU): Pre-Tx 50' 12 Posl·Tx 46 10. 
,\11 patients are alive and remam Insulin-dependent. 
0041-1345/97/$17.00 
PII S0041-1345(97)00313-8 
~~PU 
Creatinine /mg/dL) 
Current 
14 
1.2 
Graft Function 
C-peptlde (pmol/mL) 
Pre-Ix/Current 
0.3/0.4 
0.2/1.7 
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Table 2. Graft Function in 8M-Augmented and Nonaugmented Kidney + Delayed Islet Cell Transplant Recipients: 
Kidney-Delayed Islet" 
Graft Function 
Follow-up (mol 
----
Patient 
Age 
(yr)/Gender Kidney Islet 
Creat,ll,ne Img/dL) 
Current 
C-peplide (pmol/mL) 
Pre-TxtCurrent 
341M 
42/F 
AbbreViations: 8M. bone marrow: Tx, transplant. 
16 
12 
'Average Insulin requirement (IU): Pre-Tx ~ 57 :: 5 Post-Tx = 37 :': 4, 
All patients are alive and remain Insulin-dependent. 
portal vein approach. The function of the implanted islets was 
subsequently monitored by serial detection of blood glucose and 
plasma C peptide levels and by the requirement for exogenous 
insulin to maintain euglycemia, 
RESULTS AND DISCUSSION 
Infusion of delayed islets was uneventful and in all patients 
an initial increase in plasma C peptide activity was dis-
cerned. However. the necessity to reduce IS after cytomeg-
alovirus infection in two patients (one each in study [Table 
II and control [Table 2J group) precipitated moderate acute 
cellular rejection on postoperative days (PODs) 112 and 70. 
respectively. resulting in a significant decrease in plasma C 
peptide levels. In one control patient (Table 2), a very high 
(2.9 pmol/UmL) C peptide level was witnessed on POD 34 
translating into a 40% reduction in the insulin requirement. 
Albeit during the period of follow-up (3 to 15 months). two 
recipients have maintained a relatively high level of plasma 
15 
11 
1,2 
0.8 
0,02/0.4 
0.212,9 
C peptide activity (Tables I and 2). all patients nevertheless 
remain insulin-dependent. It is therefore tempting to spec-
ulate that given the partial success witnessed in these 
patients with the possibility that some may ultimately 
achieve an insulin-free existence. a much wider clinical 
application of this procedure may he warranted. 
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